Sana Biotechnology
-
Artificial Intelligence, BioPharma
Cell therapy, AI drug discovery highlight 2021’s record year in biotech IPOs
The biggest biotech IPO of 2021 belongs to a cell therapy developer that has yet to reach the clinic. Cell therapy and artificial intelligence were hot categories of newly public companies, but even though IPOs reached record levels this year that streak is not expected to continue in 2022.
-
BioPharma, Pharma, Startups, SYN
Sana Bio soars in stock market debut, raising $588M for cell & gene therapies
Sana Biotechnology is turning new science into novel medicines intended to overcome limitations of current cell therapies. After going from stealth to IPO in two years, it’s now planning to bring multiple programs into clinical testing in 2022.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Sana Biotechnology raises more than $700M for cell, gene therapy efforts
The co-founders of the company include Hans Bishop, who founded Juno Therapeutics – one of the earliest commercial developers of CAR-T cell therapy technology – in 2013.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
